# A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus

> **NCT06778967** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Gan & Lee Pharmaceuticals.** · enrollment: 1100 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus (T2DM)

## Interventions

- **DRUG:** GZR18
- **DRUG:** semaglutide

## Key facts

- **NCT ID:** NCT06778967
- **Lead sponsor:** Gan & Lee Pharmaceuticals.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-02-13
- **Primary completion:** 2026-12-11
- **Final completion:** 2026-12-11
- **Target enrollment:** 1100 (ESTIMATED)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06778967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06778967, "A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06778967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*